As of June 18, 2025, Novo Integrated Sciences Inc (NVOS) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Novo Integrated Sciences Inc's Forward P/E to Peers
To better understand Novo Integrated Sciences Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Novo Integrated Sciences Inc (NVOS) | - |
| Amedisys Inc (AMED) | 20.26 |
| Quest Diagnostics Inc (DGX) | 17.92 |
| Cryo-Cell International Inc (CCEL) | 16.90 |
| Laboratory Corporation of America Holdings (LH) | 15.80 |
| DaVita Inc (DVA) | 12.43 |
Compared to its competitors, Novo Integrated Sciences Inc's Forward P/E is difficult to compare due to insufficient data.